Summary
- Profile Type
- Research & Development Request
- POD Reference
- RDRFR20250715001
- Term of Validity
- 15 July 2025 - 15 July 2026
- Company's Country
- France
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A french biotech start-up dedicated to the development of muscle secretome-based biotherapies to cure type 1 (T1D) and type 2 (T2D) diabetes is interested to join H-JU-IHI11-T1D Topic 4 consortium or an H. EU Cl1 project. Main objective is to alleviate the burden of daily diabetes management and eliminate severe complications like renal failure. Coordinator and/or partners specialized in T1D, Stem-cells, Immune modulating specialists, biopoduction, biomarker analysis, Biosensors, AI are sought.
- Full Description
-
A french start-up, young spin-off from a the European Center of Diabetes (CeeD) which has more than 30 years of expertise in this field, is developing first-in-class biotherapies derived from the muscle secretome to treat diabetes and other metabolic diseases (NASH, obesity, etc.).
They are a preclinical stage biopharmaceutical company dedicated to developing of first-in-class biotherapies against diabetes and metabolic diseases, harvesting the breakthrough potential of the muscle secretome to regulate metabolism, a novel and unexplored approach.
Their research activites focus on achieving the first functional cure for T1D by enhancing beta cell replacement therapies (pancreatic islet or stem cell transplant). The innovation is a unique combination of pre- and post-transplant treatments based on their product, ensuring better islet survival at every step of the transplant, limiting graft rejection and enhancing its potency in the long term.
The team combines expertises in endocrinology, metabolic diseases, islet isolation process for grafts, pharmacology, molecular biology, biochemistry , primary cell cultures and cell lines (pancreatic cells, adipocytes, etc.)
Within the framework of an EU project, the company is highly interested to contribute to the development of T1D functionnal cure to alleviate the burden of daily diabetes management and eliminate severe complications like renal failure or heart stroke, which causes patients to endure expensive and debilitating treatments and reduces their life expectancy.
Timescales:
Deadline for call for proposals : 9th October (2 Stages)
They should be having all partners on board by the end of August and the proposal will be written in August and is willing to take on the coordination of certain workpackages as part of a Horizon Europe project or this H-JU-IHI11-Topic 4 call.
Partners needed:
Coordinator and/or partners from pharmaceutical companies, SME, academics, hospitals from medical and health sector with specialization in T1D, Stem-cells, Immune modulating specialists, biopoduction, biomarker analysis, Biosensors, AI are sought. - Advantages and Innovations
-
Building on 15 years of in-house R&D experience, it was demonstrated that the skeletal muscle secretome is involved in an inter-organ dialogue with the pancreas, thus establishing a molecular link between the regulation of glycaemia through the action of insulin and physical activity. This secretome contains various myokines, including a specific one discovered by the start-up lab, with revolutionary therapeutic potential, capable of regenerating the beta cells of pancreatic islets and normalising insulin secretion.
Advantages:
- Alleviate the burden of daily diabetes management
- Eliminate severe complications like renal failure, which causes patients to endure expensive and debilitating treatments and reduces their life expectancy. - Technical Specification or Expertise Sought
-
Partners with expertise in the following areas are sought :
-Stem cell manufacturing
-GMP-compliant bioproduction
-Immune modulating specialists
-Regulatory affairs (including Quality Control, Quality Assurance, and analytical methodologies)
-Biomarker analysis
-Islet graft specialists
-Cellular physiology and biochemistry
-Type 1 Diabetes (T1D) animal models
-Clinical trial investigators
-Biosensors, AI, and predictive modelling
-Medical imaging
-Health economics and cost-effectiveness analysis
-Dissemination and communication specialists - Stage of Development
- Concept stage
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- Secret know-how
Partner Sought
- Expected Role of a Partner
-
• Type: pharmaceutical companies, SME, academics, hospitals, patient organisations, healthcare providers, policy makers
• Role: project coordinator, project partners
• Task(s) to be done: Definition, contribution to the writing of the proposal and the workpackages - Type and Size of Partner
- R&D Institution
- SME 11-49
- Other
- SME 50 - 249
- SME <=10
- University
- Type of partnership
- Research and development cooperation agreement
Call details
- Framework program
- Horizon Europe
- Call title and identifier
-
HORIZON-JU-IHI-2025-11-04-two-stage
Leveraging Europe's expertise to accelerate cell therapy for type 1 diabetes - Submission and evaluation scheme
-
2 phases call of project
- Anticipated project budget
-
8825000 €
- Coordinator required
-
Yes
- Deadline for EoI
- Deadline of the call
- Project duration in weeks
-
60
- Web link to the call
- https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-JU-IHI-2025-11-04-two-stage
- Horizon Europe
Leveraging Europe's expertise to accelerate cell therapy for type 1 diabetes
Dissemination
- Technology keywords
- 06002001 - Biochemistry / Biophysics
- 06002002 - Cellular and Molecular Biology
- 06001012 - Medical Research
- 06001015 - Pharmaceutical Products / Drugs
- Market keywords
- 05005003 - Endocrinology
- Sector Groups Involved
- Health
- Targeted countries
- All countries